Fig. 1

The MAPK pathway is preferentially repressed in hypoxia by isoform-specific NPYR antagonists. ERK1/2 phosphorylation was measured in (A, C and E) MDA-MB-231 and (B, D and F) MCF7 cells treated with subtype-specific NPYR antagonists (Y1⁻ or Y5⁻) for 30 min followed by agonist stimulation in normoxia and hypoxia for 5, 15 and 30 min. A general agonist that stimulates all NPYR subtypes (NPY; A and B) or subtype-specific agonists (Y1⁺; C and D, or Y5⁺; E and F) were used. Data (n ≥ 3) represent the mean fluorescence of pERK1/2 after treatment and normalization to total ERK1/2. Each antagonist treatment is made relative to the respective agonist alone at each individual time point. Line graph with error bars representing the SEM and * represent p < 0.05 using either a one-way ANOVA and Tukey’s HSD post-hoc test or an unpaired t-test